Category: IBBJ

Junior Biotech ETF Debuts

Today, Defiance ETFs launched a third ETF, this one with a focus on small cap biotechnology companies. The Defiance Nasdaq Junior Biotechnology ETF (IBBJ) tracks an index of roughly 200 U.S. biotech companies that fall within the bottom 10% of the Nasdaq Global Index in terms of size.

The fund comes with a expense ratio of 0.45% and lists on the Nasdaq stock exchange.

“At Defiance, we believe in providing the next generation of investors with targeted exposure to disruptive themes. IBBJ does just that, offering exposure to the junior disruptors in the biotech space, and allowing investors to express either a short- or long-term view,” said Defiance ETFs CEO Matt Bielski.


Want to work with us?

A wonderful serenity has taken possession of my entire soul, like these sweet mornings of spring which I enjoy with my whole heart. I am alone, and feel the charm of existence in this spot.

Contact us